ME obtains U.S. patent for G-CSF antibody candidate

Executive Summary

• ME Therapeutics secured U.S. Patent No. 12,421,308 for its lead G‑CSF antibody candidate (H1B11‑12), protecting the amino‑acid sequence and therapeutic use in cancer.
• The company advanced cell‑line development toward GMP‑grade manufacturing and continued preclinical work on therapeutic mRNA and in‑vivo CAR programs.
• Expanded R&D capacity with two new associate research scientists to accelerate clinical‑trial preparation and broader discovery efforts.

Key Details

• Patent Grant: U.S. Patent No. 12,421,308 issued by USPTO covering the G‑CSF antibody candidate’s amino‑acid sequence and its use for cancer treatment in the United States.
• International Patents: This is the second international patent; a Chinese patent was granted in 2023.
• Cell‑Line Development: Contract research organization identified robust, stable cell lines producing the antibody; next step is selection of lead clone for GMP master cell bank creation.
• Therapeutic mRNA Program: Lead mRNA candidate demonstrated immune‑cell recruitment into tumor microenvironment in vivo; plans to test in mouse colon‑cancer model alone and with checkpoint inhibitor. Second mRNA candidate showed strong T‑cell activation in vitro, proceeding to further in‑vitro studies.
• In‑Vivo CAR Program: Discovery stage progressed; tumour‑targeted CARs confirmed active in vitro, with additional in‑vitro testing planned before moving to in‑vivo evaluation.
• Team Expansion: Two new associate research scientists hired to bolster R&D capabilities and support antibody candidate advancement toward clinical trials.

Notable Quotes

“We are pleased with the business and scientific progress we have made across our pipeline… this quarter we reached several key milestones for our lead G‑CSF antibody candidate that keep us on our pathway to the clinic, including securing a U.S. patent and moving forward cell line development in preparation for good manufacturing practices (GMP).” – Dr. Salim Dhanji, CEO, ME Therapeutics.